Document is current
Any future updates will be listed below
-
Authors
Zeuner, Simon
Vollmer, Johanna
Sigaud, Romain
Oppermann, Sina
Peterziel, Heike
ElHarouni, Dina
Oehme, Ina
Witt, Olaf
Milde, Till
Ecker, Jonas
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70113843)
- License Information
-
More Information
Article History
Received: 1 November 2023
Accepted: 27 November 2023
First Online: 7 January 2024
Declarations
:
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Olaf Witt participated in advisory boards of Astra Zeneca, BMS, Novartis, Bayer, Roche and Janssen. Olaf Witt, Ina Oehme and Till Milde received research funding from Biomed Valley and Day One Therapeutics. Ina Oehme also from PreComb. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: Not applicable.
: Not applicable.
: Not applicable.
